Cawachi Limited (JP:2664)
:2664
Want to see JP:2664 full AI Analyst Report?
Top Page
Cawachi Limited
(2664)
Select Model
Select Model
Rating:63Neutral
Price Target:
¥3,092.00
▲(2.21% Upside)
Action:Downgraded
Date:04/30/26
The score is primarily supported by balance-sheet strength (low leverage) and consistently positive cash generation, but is held back by thin margins, flat-to-declining revenue, and a recent drop in earnings. Technical indicators add a mild headwind due to negative momentum, while valuation and dividend yield provide a modest offset.
Positive Factors
Low leverage / strong balance sheet
Sustained low leverage and stable-to-growing equity provide financial resilience, lowering bankruptcy and refinancing risk. This structural strength preserves capacity to fund R&D, M&A, or dividend policy and cushions the business through cyclical pharma demand swings.
Negative Factors
Thin net and EBIT margins
Very thin operating and net margins leave limited buffer for shocks: small revenue or cost swings materially change profits. Over months this constrains reinvestment, limits free cash for strategic initiatives, and magnifies business-cycle and pricing risks.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage / strong balance sheet
Sustained low leverage and stable-to-growing equity provide financial resilience, lowering bankruptcy and refinancing risk. This structural strength preserves capacity to fund R&D, M&A, or dividend policy and cushions the business through cyclical pharma demand swings.
Read all positive factors
Cawachi Limited (2664) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥68.42B
Dividend Yield2.68%
Average Volume (3M)35.49K
Price to Earnings (P/E)―
Beta (1Y)0.36
Revenue Growth-1.15%
EPS Growth-34.48%
CountryJP
Employees2,722
SectorHealthcare
Sector Strength45
IndustryMedical - Pharmaceuticals
Share Statistics
EPS (TTM)212.49
Shares Outstanding24,583,420
10 Day Avg. Volume30,120
30 Day Avg. Volume35,490
Financial Highlights & Ratios
PEG Ratio-0.61
Price to Book (P/B)0.58
Price to Sales (P/S)0.23
P/FCF Ratio14.35
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Cawachi Limited Business Overview & Revenue Model
Company Description
Cawachi Limited manages drugstores in Japan. The company retails pharmaceuticals, health foods, childcare products, cosmetics, daily miscellaneous goods, general food products, confectionery products, etc. It also involved in the insurance busines...
Cawachi Limited Financial Statement Overview
Summary
Income Statement
56
Neutral
Balance Sheet
74
Positive
Cash Flow
63
Positive
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 287.50B | 284.49B | 287.82B | 285.96B | 281.87B | 279.46B |
| Gross Profit | 66.44B | 65.26B | 66.66B | 65.80B | 64.05B | 63.15B |
| EBITDA | 10.85B | 11.20B | 11.36B | 11.49B | 10.90B | 12.16B |
| Net Income | 4.75B | 3.20B | 4.88B | 4.71B | 4.18B | 4.83B |
Balance Sheet | ||||||
| Total Assets | 203.63B | 199.61B | 200.96B | 197.24B | 195.24B | 192.48B |
| Cash, Cash Equivalents and Short-Term Investments | 40.72B | 38.11B | 36.67B | 35.62B | 38.45B | 38.96B |
| Total Debt | 17.92B | 16.11B | 16.60B | 16.73B | 19.55B | 22.92B |
| Total Liabilities | 89.95B | 83.68B | 86.55B | 85.94B | 87.51B | 87.83B |
| Stockholders Equity | 113.68B | 115.93B | 114.41B | 111.30B | 107.72B | 104.65B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | 4.66B | 3.40B | 1.02B | 4.11B | 2.37B |
| Operating Cash Flow | 0.00 | 8.87B | 7.48B | 6.40B | 9.82B | 6.87B |
| Investing Cash Flow | 0.00 | -5.16B | -4.51B | -5.29B | -5.84B | -4.54B |
| Financing Cash Flow | 0.00 | -2.27B | -1.92B | -3.94B | -4.49B | -4.61B |
Cawachi Limited Technical Analysis
Negative
3025.00
Price Trends
3018.92
Negative
2964.48
Negative
2868.26
Positive
Market Momentum
-10.05
Positive
38.85
Neutral
6.62
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:2664, the sentiment is Negative. The current price of 3025 is above the 20-day moving average (MA) of 2997.80, above the 50-day MA of 3018.92, and above the 200-day MA of 2868.26, indicating a neutral trend. The MACD of -10.05 indicates Positive momentum. The RSI at 38.85 is Neutral, neither overbought nor oversold. The STOCH value of 6.62 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:2664.
Cawachi Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | ¥439.63B | 14.57 | 11.37% | 3.04% | 5.08% | 2.07% | |
67 Neutral | ¥368.12B | 16.82 | ― | 0.41% | 14.59% | 7.84% | |
66 Neutral | ¥580.69B | 17.44 | 15.71% | 0.96% | 15.07% | 72.98% | |
63 Neutral | ¥68.42B | -63.02 | ― | 2.68% | -1.15% | -34.48% | |
62 Neutral | ¥947.68B | 19.41 | ― | 1.72% | ― | ― | |
60 Neutral | ¥499.01B | 16.97 | ― | 0.93% | 6.74% | 6.60% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
JP:2664
Cawachi Limited
3,065.00
338.58
12.42%
JP:9989
Sundrug Co
3,760.00
-641.52
-14.57%
JP:7649
Sugi Holdings Co
3,081.00
-12.40
-0.40%
JP:3391
TSURUHA Holdings
2,106.50
-90.57
-4.12%
JP:3349
COSMOS Pharmaceutical Corporation
6,269.00
-2,744.15
-30.45%
JP:3549
KUSURI NO AOKI HOLDINGS CO.,LTD.
3,850.00
322.32
9.14%
Cawachi Limited Corporate Events
Cawachi to Cut Director Terms to One Year in Governance Revamp
Apr 28, 2026
Cawachi Limited plans to amend its Articles of Incorporation to shorten directors’ terms from two years to one year, subject to approval at the 59th Ordinary General Meeting of Shareholders on June 11, 2026. The move is aimed at clarifying m...
Cawachi Introduces Interim Dividend and Lifts Ordinary Payout to ¥100
Apr 28, 2026
Cawachi Limited’s board has approved a shift from paying only a year-end dividend to paying twice-yearly dividends, introducing an interim distribution starting in the fiscal year ending March 2027. The move is designed to enhance the medium...
Cawachi Books ¥2.1 Billion Impairment Loss for FY2025–26
Apr 28, 2026
Cawachi Limited has announced that it will record extraordinary losses for the fiscal year ended March 15, 2026, after reviewing the recoverability of non-current assets under Japan’s impairment accounting standards. The company recognized i...
Cawachi Posts Profit Slump but Lifts Dividend as It Braces for Weaker Margins
Apr 28, 2026
Cawachi Limited reported a slight 1.2% decline in net sales to ¥284.5 billion for the fiscal year ended March 15, 2026, with operating profit down 9.1% and profit attributable to owners of the parent plunging 34.5%. Despite weaker earnings an...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.